Biolevate raises €30M to bring AI-powered compliance to life sciences

Biolevate, a French AI startup focused on life sciences, has raised €30 million in Series A funding to accelerate the development of its regulatory compliance platform. The round, co-led by RAISE France and Orange Ventures, will also support the company’s expansion into the U.S. market with a new base in Boston.

Funding and expansion

Biolevate, a French AI platform specializing in life sciences, has raised €30 million in a Series A funding round, according to THE BRIDGE. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and EQT Ventures.

As part of its growth strategy, Biolevate plans to establish a new base in Boston, U.S. The move is expected to support its expansion in the North American market, a key hub for pharmaceutical and biotech innovation.

AI for regulated industries

Biolevate’s platform is designed to address a critical need in the life sciences sector: creating regulatory-compliant documents with full traceability. According to THE BRIDGE, the company’s evidence-grade AI platform ensures that scientific and regulatory knowledge is managed in a way that allows for an Evidence Trail—a system that tracks the knowledge referenced by AI, the decisions it makes, and the procedures it executes.

The platform targets high-stakes operations such as clinical trials, regulatory submissions, and drug discovery. For example, in protocol creation, the AI generates drafts while attaching links to evidence for each statement, ensuring that final decisions remain with human reviewers. This approach aims to reduce errors and accelerate approvals without compromising compliance.

Biolevate claims its platform has reduced time to market by up to 50% in specific pharmaceutical processes. This efficiency gain is particularly valuable in an industry where delays can cost millions and slow down patient access to treatments.

Partnerships and use cases

Biolevate is collaborating with Enovalife, a subsidiary of Orange Business, to automate tasks like protocol creation, Clinical Study Reports (CSR), and "regulatory bridging." The latter involves adapting documents to meet country-specific regulatory requirements, a complex and time-consuming process in global drug development.

Orange’s involvement extends beyond funding. According to THE BRIDGE, the company’s agentic AI integrates verified scientific and regulatory knowledge into operations, further enhancing Biolevate’s platform. This partnership highlights how startups can leverage corporate expertise to refine their product offerings.

What this means

LazyFounders analysis — our interpretation, not reported fact.

Biolevate’s funding and expansion reflect a growing trend: AI is becoming indispensable in highly regulated industries like life sciences. For founders, this deal underscores two key insights.

First, regulatory compliance is a moat. Many AI startups focus on generic use cases, but Biolevate’s "evidence-grade" approach targets a pain point—traceability—that incumbents struggle to solve. This isn’t just about automation; it’s about building trust with regulators and auditors. Startups in pharma, healthcare, or finance should ask: Where are the bottlenecks that AI can address without cutting corners on compliance?

Second, corporate venture capital (CVC) is a strategic lever. Orange Ventures isn’t just writing a check; it’s bringing a partner (Orange Business) that can integrate Biolevate’s technology into real-world workflows. For founders raising capital, CVCs can offer more than money—they can unlock access to pilot customers, domain expertise, and distribution channels. The caveat? Alignment matters. Ensure your lead investor’s goals extend beyond financial returns to include product adoption or market expansion.

Key takeaways

• Biolevate secures €30M in Series A funding co-led by RAISE France and Orange Ventures.
• The company will establish a new base in Boston, U.S., to expand its global footprint.
• Biolevate’s AI platform is designed for regulated life sciences operations, ensuring compliance and traceability.
• The platform has demonstrated a 50% reduction in time to market for certain pharmaceutical processes.
• Additional investors include MSD Global Health Innovation Fund, Station F, and EQT Ventures.

FAQ

What is Biolevate’s core technology?

Biolevate’s evidence-grade AI platform automates the creation of regulatory documents in the life sciences sector. Its Evidence Trail feature ensures traceability by tracking AI-generated decisions, referenced knowledge, and verification steps.

Why is Boston a strategic location for Biolevate?

Boston is a global hub for pharmaceutical and biotech companies, making it an ideal location for Biolevate to expand its footprint in the U.S. market. The city’s ecosystem offers access to talent, partners, and potential customers in the life sciences industry.

How does Biolevate’s platform improve efficiency in pharmaceutical processes?

Biolevate claims its platform can reduce time to market by up to 50% in specific pharmaceutical processes. By automating document creation and ensuring compliance with regulatory requirements, the platform minimizes errors and accelerates approvals.

What role do corporate investors like Orange Ventures play in Biolevate’s growth?

Corporate investors like Orange Ventures provide more than just funding. They offer strategic support, such as access to enterprise customers (via Orange Business), domain expertise, and integration opportunities for Biolevate’s AI platform.

Related on LazyFounders

• More startup news